{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:10:05Z","timestamp":1788577805994,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV) infection remains highly prevalent in Pakistan, particularly among patients with multiple comorbid conditions. Despite the widespread availability of direct-acting antivirals (DAAs), practical machine learning approaches to predict sustained virological response (SVR) are still lacking in resource-limited settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study analyzed 221 comorbid HCV patients treated with Sofosbuvir + Daclatasvir \u00b1 Ribavirin combination therapy. Baseline demographic and laboratory parameters were preprocessed using standard scaling methods. The dataset was split into 70% training and 30% testing subsets, and class imbalance in the training set was addressed using SMOTE. Five machine learning models, logistic regression, decision tree, random forest, XGBoost, and SVM, were tuned using stratified five-fold cross-validation. Evaluation metrics, including accuracy, precision, recall, specificity, F1-score, and ROC-AUC, were used to assess test-set performance, and SHAP analysis was conducted for the top-performing model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 221 patients, 162 (73%) achieved SVR. Random Forest and SVM demonstrated the best discriminatory performance, with Random Forest achieving the highest accuracy (0.73), precision (0.84), and F1-score (0.81), while SVM produced the highest recall (0.82) and ROC-AUC (0.76). ALT and AST consistently emerged as the strongest predictors associated with treatment failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings support the potential of ML-based decision tools using routine clinical data in high-burden, resource-limited settings to guide risk stratification, optimize monitoring intensity, and inform public health strategies for HCV control and elimination in Pakistan and highlight the need for broader validation across larger, multicenter cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1783217","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:45:14Z","timestamp":1776059114000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Machine learning-based prediction of treatment response in comorbid hepatitis C patients receiving DAA therapy: a real-world study from Pakistan"],"prefix":"10.3389","volume":"14","author":[{"given":"Dur E","family":"Nishwa","sequence":"first","affiliation":[{"name":"Department of Precision Medicine, Sungkyunkwan University, School of Medicine","place":["Suwon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Abbas","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, College of IT Convergence, Gachon University","place":["Seongnam, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, Sungkyunkwan University, School of Medicine","place":["Suwon, Republic of Korea"]},{"name":"Department of Artificial Intelligence, Sungkyunkwan University","place":["Suwon, Republic of Korea"]},{"name":"Department of Metabiohealth, Sungkyunkwan University","place":["Suwon, Republic of Korea"]},{"name":"Personalized Cancer Immunotherapy Research Center, Sungkyunkwan University, School of Medicine","place":["Suwon, Republic of Korea"]},{"name":"Department of Family Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","volume-title":"Global Hepatitis Report 2024: Action For Access In Low-And Middle-Income Countries","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e14050","DOI":"10.1111\/jvh.14050","article-title":"A health systems strengthening approach to address the high burden of hepatitis C in Pakistan","volume":"32","author":"Qureshi","year":"2025","journal-title":"J Viral Hepat."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101573","DOI":"10.1016\/j.bjid.2021.101573","article-title":"A real-life study of the positive response to DAA-based therapies for hepatitis C in Brazil","volume":"25","author":"Vivaldini","year":"2021","journal-title":"Braz J Infect Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12913-021-07289-0","article-title":"Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa","volume":"22","author":"Boyer","year":"2022","journal-title":"BMC Health Serv Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jval.2020.03.018","article-title":"Cost-utility analysis of direct-acting antivirals for treatment of chronic hepatitis C genotype 1 and 6 in Vietnam","volume":"23","author":"Due","year":"2020","journal-title":"Value Health."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2217\/fvl-2023-0193","article-title":"Treatment response and adverse effects of direct acting antivirals among HCV patients carrying comorbid conditions","volume":"19","author":"Nishwa","year":"2024","journal-title":"Future Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/hep.32347","article-title":"Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: an HCV-TARGET analysis","volume":"76","author":"Park","year":"2022","journal-title":"Hepatology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6054677","DOI":"10.1155\/2022\/6054677","article-title":"Determination of risk factors associated with the failure of 12 weeks of direct-acting antiviral therapy in patients with hepatitis C: a prospective study","volume":"2022","author":"Nguyen Thi Thu","year":"2022","journal-title":"Biomed Res Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"20936","DOI":"10.1038\/s41598-025-06290-5","article-title":"Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes","volume":"15","author":"Brzdek","year":"2025","journal-title":"Sci Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3390\/v11090850","article-title":"Hepatitis B virus (HBV) reactivation following pharmacological eradication of hepatitis C virus (HCV)","volume":"11","author":"Pisaturo","year":"2019","journal-title":"Viruses."},{"key":"B12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s43066-023-00257-9","article-title":"Outcome of direct-acting antiviral treatment in patients with hepatitis C virus\/hepatitis B virus coinfection","volume":"13","author":"Shalaby","year":"2023","journal-title":"Egypt liver j."},{"key":"B13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4254\/wjh.v10.i9.612","article-title":"Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c","volume":"10","author":"Dong","year":"2018","journal-title":"World J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/hep.24550","article-title":"Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e16169","DOI":"10.1016\/j.heliyon.2023.e16169","article-title":"Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis","volume":"9","author":"Riaz","year":"2023","journal-title":"Heliyon."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7833","DOI":"10.3390\/jcm13247833","article-title":"AI in hepatology: revolutionizing the diagnosis and management of liver disease","volume":"13","author":"Malik","year":"2024","journal-title":"J Clin Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.gastha.2024.01.007","article-title":"A machine learning model to predict risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease","volume":"3","author":"Sarkar","year":"2024","journal-title":"GHA."},{"key":"B18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1109\/TCBB.2017.2690848","article-title":"Comparison of machine learning approaches for prediction of advanced liver fibrosis in chronic hepatitis C patients","volume":"15","author":"Hashem","year":"2017","journal-title":"IEEE\/ACM TCBB."},{"key":"B19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40537-024-00944-3","article-title":"Feature reduction for hepatocellular carcinoma prediction using machine learning algorithms","volume":"11","author":"Mostafa","year":"2024","journal-title":"J Big Data"},{"key":"B20","first-page":"209","article-title":"An analysis of hepatitis C virus prediction using different data mining techniques International","volume":"3","author":"Radwan","year":"2013","journal-title":"IJCSEITR."},{"key":"B21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s40537-024-01011-7","article-title":"Advances in ECG and PCG-based cardiovascular disease classification: a review of deep learning and machine learning methods","volume":"11","author":"Ameen","year":"2024","journal-title":"J Big Data."},{"key":"B22","doi-asserted-by":"publisher","first-page":"14495","DOI":"10.1038\/s41598-023-41545-z","article-title":"Utilizing convolutional neural networks to classify monkeypox skin lesions","volume":"13","author":"Eliwa","year":"2023","journal-title":"Sci Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12859-023-05456-0","article-title":"IHCP: interpretable hepatitis C prediction system based on black-box machine learning models","volume":"24","author":"Fan","year":"2023","journal-title":"BMC Bioinform."},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1109\/ICSSES62373.2024.10561391","article-title":"AI based solution for predicting hepatitis C virus from blood samples","volume-title":"2024 International Conference on Smart Systems for applications in Electrical Sciences (ICSSES)","author":"Bharathi","year":"2024"},{"key":"B25","article-title":"Comparative Analysis of Machine Learning Algorithms for Hepatitis C Virus (HCV) Prediction","volume-title":"50th International Conference on Computers and Industrial Engineering: Sustainable Digital Transformation, CIE 2023","author":"Toffaha","year":"2023"},{"key":"B26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.14218\/JCTH.2018.00014","article-title":"Zhang, Hu K-Q, Hepatitis C virus clearance by direct-acting antiviral results in rapid resolution of hepatocytic injury as indicated by both alanine aminotransferase and aspartate aminotransferase normalization","volume":"6","author":"Huynh","year":"2018","journal-title":"J clin transl hepatol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S292139","article-title":"Predicting hepatocellular carcinoma risk in patients with chronic HCV infection and a sustained virological response to direct-acting antivirals","author":"D'Ambrosio","year":"2021","journal-title":"J Hepatocell Carcinoma."},{"key":"B28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.4254\/wjh.v5.i9.496","article-title":"Hepatitis C genotype 6: a concise review and response-guided therapy proposal","volume":"5","author":"Bunchorntavakul","year":"2013","journal-title":"World J Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/cld.442","article-title":"New treatments for HCV: perspective from Asia","volume":"5","author":"Yu","year":"2015","journal-title":"CLD."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1007\/s10115-023-01851-4","article-title":"Hepatitis C virus prediction based on machine learning framework: a real-world case study in Egypt","volume":"65","author":"Mamdouh Farghaly","year":"2023","journal-title":"KAIS."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.3390\/jcm13102939","article-title":"A machine learning-based mortality prediction model for patients with chronic hepatitis C infection: an exploratory study","volume":"13","author":"Al Alawi","year":"2024","journal-title":"J Clin Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"104562","DOI":"10.1016\/j.ijmedinf.2021.104562","article-title":"Machine-learning-based predictions of direct-acting antiviral therapy duration for patients with hepatitis C","volume":"154","author":"Feldman","year":"2021","journal-title":"Int J Med Inform."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1783217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:45:16Z","timestamp":1776059116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1783217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":32,"alternative-id":["10.3389\/fpubh.2026.1783217"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1783217","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1783217"}}